Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Report 2026

The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market size has grown rapidly in recent years. It will grow from $1.06 billion in 2025 to $1.22 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing cervical cancer screening program coverage, adoption of molecular diagnostics in gynecology, rising awareness of hr-hpv infection risks, availability of automated pcr platforms, expansion of centralized diagnostic laboratories.

The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market size is expected to see rapid growth in the next few years. It will grow to $2.12 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to increasing shift toward primary hpv screening, growing demand for high-specificity cancer risk stratification, expansion of population-based screening programs, integration of digital pathology and reporting systems, increasing investments in precision diagnostics. Major trends in the forecast period include increasing adoption of mrna-based primary cervical screening assays, growing use of fully automated molecular testing platforms, rising integration of genotype-specific reflex testing, expansion of high-specificity screening algorithms, enhanced focus on clinically actionable hpv detection.

The increasing prevalence of cervical cancer is expected to accelerate the expansion of the cervical human papillomavirus messenger ribonucleic acid testing market going forward. Cervical cancer is a malignant condition that develops in cervical cells, primarily caused by persistent infection with high-risk human papillomavirus types, and remains a major contributor to cancer-related illness and mortality among women globally. The growing prevalence of cervical cancer is linked to low participation in cervical screening programs, resulting in delayed detection and progression of persistent HPV infections into cancer. Cervical human papillomavirus messenger ribonucleic acid testing supports early identification of active high-risk HPV infections, improves risk classification, and enables timely intervention to reduce disease progression. For example, in December 2025, according to Cancer Australia, an Australia-based government agency, there were 265 deaths from cervical cancer in 2023, and it was estimated that there would be 254 deaths in 2025. Therefore, the increasing prevalence of cervical cancer is strengthening the growth of the cervical human papillomavirus messenger ribonucleic acid testing market.

Leading companies operating in the cervical human papillomavirus messenger ribonucleic acid (mRNA) testing market are concentrating on developing technological advancements, such as multiplex real-time PCR innovations, to gain competitive advantage by improving diagnostic accuracy, enabling simultaneous E6/E7 mRNA detection and high-risk HPV genotyping, reducing false positives, lowering testing costs, and expanding adoption. Multiplex real-time PCR innovations refer to the capability to detect and quantify multiple HPV E6/E7 mRNA targets and high-risk genotypes simultaneously in a single PCR reaction, improving accuracy, efficiency, and clinical relevance of cervical HPV testing. For instance, in July 2024, Medicon Hellas S.A., a Greece-based diagnostics company, introduced the multiplex real-time PCR kit for HPV E6/E7 mRNA genotyping as the exclusive distributor for Uni-Medica in Greece and Cyprus. The kit features compatibility with multiple PCR instruments such as Bio-Rad CFX96 and Hongshi SLAN-96 series for fluorochrome analysis with Ct values, applicability to diverse samples including semen, urine, and anal swabs beyond cytology, and CE-IVD marking with results available in 2.5 hours.

In April 2025, Institut Pasteur, a France-based organization focused on biomedical research, translational science, and infectious disease innovation, partnered with ABL Diagnostics. The objective of this partnership is to commercialize and scale advanced HPV RNA sequencing technology by integrating Institut Pasteur’s HPV RNA-seq intellectual property into ABL Diagnostics’ molecular diagnostic portfolio, thereby strengthening technological expertise and expanding high-risk HPV diagnostic offerings. ABL Diagnostics is a France-based provider of molecular diagnostic solutions, specializing in viral load testing, infectious disease assays, and advanced RNA-based diagnostic technologies for clinical and public health use.

Major companies operating in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Co-Dx Ltd., Promega Corporation, Seegene Inc., Molbio Diagnostics, QIAGEN N.V., Sansure Biotech Inc., Xiamen Zeesan Biotech Co. Ltd., DiaCarta Inc., Operon S.A., AB ANALITICA s.r.l., Arbor Vita Corporation, Mylab Discovery Solutions, Guangdong Hybribio Biotech Co. Ltd., Atila Biosystems, GeneFirst Ltd., Advanced Molecular Diagnostics.

Tariffs are impacting the cervical HPV mRNA testing market by increasing costs of imported molecular reagents, enzymes, primers, probes, automated analyzers, and nucleic acid extraction systems used across screening and diagnostic workflows. Diagnostic laboratories and hospital networks in North America and Europe are most affected due to reliance on imported assay kits and instruments, while Asia-Pacific faces pricing pressure on export-oriented diagnostic manufacturing. These tariffs are increasing per-test costs and slowing procurement cycles for public screening programs. However, they are also encouraging local reagent production, regional assay development, and domestic manufacturing of molecular diagnostic platforms, strengthening long-term testing infrastructure resilience.

The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market research report is one of a series of new reports that provides cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market statistics, including cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing industry global market size, regional shares, competitors with a cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market share, detailed cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market segments, market trends and opportunities, and any further data you may need to thrive in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing industry. This cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing is a molecular diagnostic technique that identifies the expression of E6/E7 oncogenic mRNA from high-risk HPV strains in cervical specimens, indicating an active infection that is directly involved in cervical cellular transformation. In contrast to HPV DNA tests that only confirm the presence of viral genetic material, mRNA testing offers greater specificity for clinically relevant infections associated with an increased risk of cervical precancerous lesions and cancer.

The primary product types of cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing include assay kits, instruments, and reagents and consumables. Assay kits refer to ready-to-use kits developed to detect and quantify HPV mRNA for the early diagnosis and screening of cervical cancer. These products are applied across areas including cervical cancer screening, research, and other applications, and are used by end users including hospitals and clinics, diagnostic laboratories, research institutes, and other end users.

The cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing market consists of sales of molecular diagnostic products, primary cervical screening assays, genotyping add-ons, fully automated platform assays, laboratory-developed tests, experimental kits, and integrated screening panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.